StocktoriaNewcelX Ltd. NCEL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$2.6M | -$2.1M | -$3.0M | -$15.5M | -$11.9M |
| Net income | -$8.3M | -$7.2M | -$3.3M | -$16.5M | -$11.9M |
| Operating cash flow | -$2.8M | -$1.1M | -$3.4M | -$13.9M | -$14.9M |
| Free cash flow | -$2.8M | -$1.1M | -$3.5M | — | -$15.0M |
| Total assets | $11.4M | $903,000 | $1.8M | $9.3M | $5.8M |
| Total liabilities | $4.2M | $8.9M | $10.7M | $6.0M | $5.2M |
| Shareholders' equity | $7.2M | -$8.0M | -$1.2M | $111,000 | $542,388 |
| Ratios | |||||
| Return on assets | -72.5% | -797.0% | -180.4% | -177.8% | -207.2% |
| Return on equity | -114.5% | 90.0% | 278.4% | -14861.0% | -2202.5% |
| Current ratio | 0.76 | 0.09 | 0.23 | 2.75 | 2.38 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001783036 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.